News - prasugrel


Current filters:


Popular Filters

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study


Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo files for Japanese approval of Prasugrel


Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

Daiichi Sankyo updates on PRASFIT-Elective study, NDA filing


Japanese drug major Daiichi Sankyo (TYO: 4568) says that the follow-up period for the Phase III PRASFIT-Elective…

Asia-PacificAspirinCardio-vascularDaiichi SankyoEffientPharmaceuticalprasugrelRegulationResearch

Daiichi Sankyo to file prasugrel in Japan next year, following strong results


Japanese drug major Daiichi Sankyo (TYO: 4568) has announced data from the PRASFIT-ACS study, a double-blind…

Asia-PacificCardio-vascularDaiichi SankyoPharmaceuticalprasugrelRegulationResearch

Updated AHA/ACCF guidelines for unstable angina include newest blood-thinning drug


Ticagrelor, Anglo-Swedish drug major AstraZeneca's (LSE: AZN) blood-thinning drug Brilique/Brilinta which…

AspirinAstraZenecaBrilintaBriliqueCardio-vascularClopidogrelNorth AmericaPharmaceuticalprasugrelRegulation

Back to top